Contact this trialFirst, we need to learn more about you.
Pembrolizumab + Lenvatinib with/without FMT for Melanoma
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial will study how adding microbiome therapy to an existing treatment for PD-1 refractory melanoma affects outcomes over 104 weeks in patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service